Management of Malignancy-Associated Pleural Effusion
Tóm tắt
Từ khóa
Tài liệu tham khảo
Light RW. Pleural diseases. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2001
Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J 1997; 10: 1097–13
Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000; 117: 79–86
Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63: 695–702
Martinez-Morangón E, Aparicio J, Sanchis J, et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998; 65: 108–13
Mcloud TC, Isler R, Head J. The radiological appearance of chemical pleurodesis. Radiology 1980; 135: 313–7
Grodzin CJ, Balk RA. Indwelling small pleural catheter needle thoracentesis in the management of large pleural effusions. Chest 1997; 111: 981–8
Petrou M, Kaplan D, Goldstraw P. Management of malignant pleural effusions: the complementary role of talc pleurodesis and pleuroperitoneal shunting. Cancer 1995; 75: 801–5
Good JT, Taryle DA, Sahn SA. The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 1985; 131: 737–41
Sahn SA, d Good Jr JT. Pleural fluid pH in malignant effusions: diagnostic, prognostic and therapeutic implications. Ann Intern Med 1988; 108: 345–9
Rodríguez-Panadero F, López Mejías J. Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989; 139: 663–7
Aelony Y, King RR, Boutin C. Thoracoscopic talc poudrage in malignant pleural effusions: effective pleurodesis despite low pleural pH. Chest 1998; 113: 1007–12
Bethune N. Pleural poudrage: a new technic for the deliberate production of pleural adhesions as a preliminary to lobectomy. J Thoracic Surg 1935; 4: 251–61
Sherman S, Grady KJ, Seidman JC. Clinical experience with tetracycline for pleurodesis of malignant effusions. South Med J 1987; 80: 716–9
Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120: 56–64
Martinez-Morangon E, Aparicio J, Rogado MC, et al. Pleurodesis in malignant effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 1997; 10: 2380–3
Patz EF, McAdams P, Erasmus JJ, et al. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998; 113: 1305–11
Marchi E, Vargas FS, Teixeira LR, et al. Comparison of nitrogen mustard, cytarabine and dacarbazine as pleural sclerosing agents in rabbits. Eur Respir J 1997; 10: 598–602
Hillerdal G, Kiviloog J, Nöu E, et al. Corynebacterium parvum in malignant effusion: a randomized prospective study. Eur J Respir Dis 1986; 69: 204–6
Rossi GA, Felletti R, Balbi B, et al. Symptomatic treatment of recurrent malignant pleural effusions with intrapleurally administered Corynebacterium parvum. Am Rev Respir Dis 1987; 135: 885–90
Luh K-T, Yang P-C, Kuo S-H, et al. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer: a randomized trial. Cancer 1992; 69: 674–9
Shimizu J, Hayashi Y, Oda M, et al. Treatment of postoperative chylothorax by pleurodesis with the streptococcal preparation OK-432. Thorac Cardiovasc Surg 1994; 42: 233–6
Kataoka M, Morishita R, Hiramatsu J, et al. OK-432 induces production of neutrophil chemotactic factors in malignant pleural effusion. Intern Med 1995; 34: 352–6
Agrenius V, Chmielewska J, Widström O, et al. Increased coagulation activity of the pleura after tube drainage and quinacrine instillation in malignant pleural effusion. Eur Respir J 1991; 4: 1135–9
Koldsland S, Svennevig JL, Lehne G, et al. Chemical pleurodesis in malignant pleural effusions: a randomized prospective study of mepacrine versus bleomycin. Thorax 1993; 48: 790–3
Light RW, Cheng DS, Lee YC, et al. A single intrapleural injection of transforming growth factor-beta (2) produces an excellent pleurodesis in rabbits. Am J Respir Crit Care Med 2000; 162: 98–104
Gary Lee YC, Melkerneker D, Thompson PJ, et al. Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit Care Med 2002; 165: 88–94
Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999; 54: 707–10
Rosso R, Rimoldi R, Salvati F, et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 1988; 45: 253–6
Yanagawa H, Haku T, Hiramatsu K, et al. Intrapleural instillation of interferon gamma in patients with malignant pleurisy due to lung cancer. Cancer Immunol Immunother 1977; 45: 93–9
Wilkins HE, Connolly MM, Grays P, et al. Recombinant interferon alpha-2b in the management of malignant pleural effusions. Chest 1997; 111: 1597–9
Lissoni P, Mandala M, Curigliano G, et al. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. Oncology 2001; 60: 308–12
Rauthe G, Sistermanns J. Recombinant tumor necrosis factor in the local therapy of malignant pleural effusion. Eur J Cancer 1997; 33: 226–31
de Campos JR, Vargas FS, Werebe EC, et al. Thoracoscopy talc poudrage: a 15-year experience. Chest 2001; 119: 801–6
Haupt GJ, Camishion RC, Templeton III JY. Treatment of malignant pleural effusion by talc poudrage. JAMA 1960; 172: 918–21
Camishion RC, Gibbon JH, Nealton Jr TF. Talc poudrage in the treatment of pleural effusion due to cancer. Surg Clin North Am 1962; 42: 1521–6
Pearson FG, MacGregor DC. Talc poudrage for malignant pleural effusion. J Thorac Cardiovasc Surg 1966; 51: 732–8
Jones GR. Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis. Thorax 1969; 24: 69–73
Adler RH, Sayek I. Treatment of malignant pleural effusion: a method using the thoracostomy and talc. Ann Thorac Surg 1976; 22: 8–15
Fentiman IS, Rubens RD, Hayward JL. Control of pleural effusions in patients with breast cancer. Cancer 1983; 52: 737–79
Fentiman IS, Rubens RD, Hayward JL. A comparison of intracavitary talc and tetracycline for the control of pleural effusions secondary to breast cancer. Eur J Cancer Clin Oncol 1986; 22: 1079–81
Weissberg D, Ben-Zeev I. Talc pleurodesis. Experience with 360 patients. J Thorac Cardiovasc Surg 1993; 106: 689–95
Aelony Y, King R, Boutin C. Thoracoscopy talc poudrage pleurodesis for chronic recurrent pleural effusions. Ann Intern Med 1991; 115: 778–82
Webb WR, Ozmen V, Moulder PV, et al. Iodized talc pleurodesis for the treatment of pleural effusions. J Thorac Cardiovasc Surg 1992; 103: 885–6
Hartman DL, Gaither JM, Kesler KA, et al. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993; 105: 743–8
Rodriguéz-Panadero F, Segado A, Martin JJ, et al. Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 1995; 151 (3 Pt 1): 785–790s
Chambers JS. Palliative treatment of neoplastic pleural effusion with intercostal intubation and talc instillation. West J Surg Obst & Gynec 1958; 66: 26–8
Viallat JR, Rey F, Astoul P, et al. Thoracoscopic talc poudrage pleurodesis for malignant pleural effusions: a review of 360 cases. Chest 1997; 110: 1387–93
Rehse DH, Aye RW, Florence MG. Respiratory failure after talc pleurodesis. Am J Surg 1999; 177: 437–40
Ferrer J, Villarino MA, Tura JM, et al. Talc preparations used for pleurodesis vary markedly from one preparation to another. Chest 2001; 119: 1901–5
Sanches C, Marchi E, Romero B, et al. Association of the size of talc particles with the occurrence of complications of pleurodesis. Eur Respir J 2001; 18: 515S–6S
Werebe EC, Pazetti R, Campos JRM, et al. Systemic distribution of talc after intrapleural administration in rats. Chest 1999; 115: 190–3
Rubinson RM, Bolooki H. Intrapleural tetracycline for control of malignant pleural effusion: a preliminary report. South Med J 1972; 65: 847–8
Thorsrud GK. Pleural reactions to irritants: an experimental study with special references to pleural adhesions and concrescence in relation to pleural turnover of fluid. Acta Chir Scand 1965; 355: 1–74
Light RW, O’Hare VS, Moritz TE, et al. Intrapleural tetracycline for the prevention of recurrent spontaneous pneumothorax: results of a department of veterans’ affairs cooperative study. JAMA 1990; 264: 2224–30
Bayly TC, Kisner DL, Sybert A, et al. Tetracycline and quinacrine in the control of malignant pleural effusions. Cancer 1978; 41: 1188–92
Antony VB, Rothfuss KJ, Godbey SW, et al. Mechanism of tetracycline-hydrochloride-induced pleurodesis: tetracycline-hydrochloride-stimulated mesothelial cells produce a growth factor-like activity for fibroblasts. Am Rev Respir Dis 1992; 146: 1009–13
Baumann MH, Heinrich K, Sahn SA, et al. Pleural macrophages differentially after mesothelial cell growth and collagen production. Inflammation 1993; 17: 1–12
Kitamura S, Sugiyama Y, Izumi T, et al. Intrapleural doxycycline for control of malignant pleural effusion. Curr Ther Res 1981; 30: 515–21
Zaloznik AJ, Oswald SG, Langin M. Intrapleural tetracycline in malignant pleural effusions: a randomized trial. Cancer 1983; 51: 752–5
Leahy BC, Honeybourne D, Brear SG, et al. Treatment of malignant pleural effusion with intrapleural Corynebacterium parvum or tetracycline. Eur J Respir Dis 1985; 66: 50–4
Muir JF, Deffouilloy C, Ndarurunze S., et al. The use of intrapleural doxycycline by lavage: drainage in recurrent effusions of neoplastic origin. Rev Mal Respir 1987; 4: 29–33
Gravelyn TR, Michelson MK, Gross BH, et al. Tetracycline pleurodesis for malignant pleural effusions. Cancer 1987; 59: 1973–7
Mansson T. Treatment of malignant pleural effusion with doxycycline. Scand J Infect Dis 1988; 53: 29–34
Landvater L, Hix WR, Mills M, et al. Malignant pleural effusion treated by tetracycline therapy. Chest 1988; 93: 1196–8
Hatta T, Tsubuota N, Yoshimura M, et al. Effect of intrapleural administration of minocycline on postoperative air leakage and malignant pleural effusion. Kyobu Geka 1990; 43: 283–6
Loutsidis A, Bellenis I, Argiriou M, et al. Tetracycline compared with mechlorethamine in the treatment of malignant pleural effusions: a randomized trial. Respir Med 1994; 88: 523–6
Sahn SA, Good JT. The effect of common sclerosing agents on the rabbit pleural space. Am Rev Respir Dis 1981; 124: 65–7
Light RW, Wang NS, Sassoon CSH, et al. Comparison of the effectiveness of tetracycline and minocycline as pleural sclerosing agents in rabbits. Chest 1994; 106: 577–82
Light RW, Sassoon CSH, Vargas FS, et al. Influence of dose and concentration of minocycline in induced pleurodesis in rabbits [abstract]. Chest 1992; 102: 177S
Vargas FS, Light RW, Sassoon CSH, et al. Comparison of the effectiveness of bleomycin, mitoxantrone and minocycline as pleural sclerosing agents in rabbits [abstract]. Chest 1992; 102: A524
Dryzer SR, Joseph J, Baumann M, et al. Early inflammatory response of minocycline and tetracycline on the rabbit pleura. Chest 1993; 104: 1585–8
Strange C, Birminghan K, Dryzer S, et al. Minocycline and tetracycline are rapidly absorbed through the rabbit pleural space [abstract]. Am Rev Resp Dis 1993; 147: A795
Palladine W, Cunningham TJ, Sponzo R, et al. Intracavitary bleomycin in the management of malignant effusions. Cancer 1976; 38: 1903–8
Bitran JD, Brown C, Desser RK, et al. Intracavitary bleomycin for the control of malignant effusions. J Surg Oncol 1981; 16: 273–6
Ostrowski MJ. An assessment of long-term results of controlling the reaccumulation of malignant effusions using intracavitary bleomycin. Cancer 1986; 57: 721–7
Ruckdeschel JC, Moores D, Lee J, et al. Intrapleural therapy for malignant pleural effusions: a randomized comparison of bleomycin and tetracycline. Chest 1991; 100: 1528–35
Vargas FS, Wang NS, Lee HM, et al. Effectiveness of bleomycin in comparison to tetracycline as pleural sclerosing agent in rabbits. Chest 1993; 104: 1582–4
Kessinger A, Wington RS. Intracavitary bleomycin and tetracycline in the management of malignant pleural effusions: a randomized study. J Surg Oncol 1987; 36: 81–3
Hamed H, Fentiman IS, Chaudary MA, et al. Comparison of intracavitary bleomycin and talc for the control of pleural effusions secondary to carcinoma of the breast. Br J Surg 1989; 76: 1266–7
Maiche AG, Virkkunen T, Kontkanen T, et al. Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. Am J Clin Oncol 1993; 16: 50–3
Reynolds JEF. Martindale: the extra pharmacopoeia. 30th ed. London: The Pharmaceutical Press, 1993
Leone RR, Corsetti HI, Vicario GP, et al. Hidroxido de sodio intrapleural para el control del derrame metastatico. Prensa Med Argent 1982; 69: 764–7
Leone RR, Vicario GP. Estudio clinico experimental em la sinfisis pleural por accion del hidroxido de sodio. Rev Argent Cir 1985; 48: 143–8
Leone RR, Jacovella PF, Vicario GF, et al. Derrame pleural neoplasico. Rev Argent Cir 1990; 58: 74–81
Guachalla JU, Herrera MH, Nuñez HR, et al. Evaluacion de la pleurodesis com hidroxido de sodio en el derrame pleural maligno. Rev Chil Cir 1987; 39: 288–92
Teixeira LR, Vargas FS, Carmo AO, et al. Effectiveness of sodium hydroxide as a pleural sclerosing agent in rabbits: influence of concomitant intrapleural lidocaine. Lung 1996; 174: 325–32
Andersen I, Poulsen T. Surgical treatment of spontaneous pneumothorax. Acta Chir Scand 1959; 118: 105–12
Wied U, Halkier E, Hoeier-Madsen K, et al. Tetracycline versus silver nitrate pleurodesis in spontaneous pneumothorax. Thorac Cardiovasc Surg 1983; 86: 591–3
Hopkirk JAC, Pullen MJ, Fraser JR. Pleurodesis: the results of treatment for spontaneous pneumothorax in the Royal Air Force. Aviat Space Environ Med 1983; 54: 158–60
Vargas FS, Teixeira LR, Silva LMMF, et al. Comparison of silver nitrate and tetracycline as pleural sclerosing agents in rabbits. Chest 1995; 108: 1080–3
Vargas FS, Teixeira LR, Antonangelo L, et al. Experimental pleurodesis in rabbits induced by silver nitrate and talc: 1-year follow-up. Chest 2001; 119: 1516–20
Vargas FS, Teixeira LR, Vaz MAC, et al. Silver nitrate is superior to talc slurry in producing pleurodesis in rabbits. Chest 2000; 118: 808–13
Vargas FS, Carmo AO, Marchi E, et al. Effectiveness of silver nitrate (SN) compared to talc slurry as pleural sclerosing agent in rabbits: influence of concomitant intrapleural lidocaine. Rev Hosp Clin Fac Med Sao Paulo 1999; 54: 199–208
Paschoalini MS, Pereira JR, Abdo EF, et al. Silver nitrate versus talc slurry for pleurodesis in patients with malignant pleural effusions [abstract]. Am J Respir Crit Care Med 1999; 159: A384
Vargas FS, Antonangelo L, Capelozzi V, et al. Lung damage in experimental pleurodesis induced by silver nitrate or talc: 1-year follow-up. Chest 2002; 122(6): 2122–6
Anthony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162: 1987–2001
van den Heuvel MM, Smith HJ, Barbierato SB, et al. Talc-induced inflammation in the pleural cavity. Eur Respir J 1998; 12: 1419–23
Miller EJ, Kajikawa O, Pueblitz S, et al. Chemokine involvement in tetracycline-induced pleuritis. Eur Respir J 1999; 14: 1387–93
Marchi E, Liu W, Broaddus VC. Mesothelial cell apoptosis is confirmed in vivo by morphological change in cytokeratin distribution. Am J Physiol Lung Cell Mol Physiol 2000; 278: L528–35
Nasreen N, Mohammed KA, Dowling PA, et al. Talc induces apoptosis in human malignant mesothelioma cells in vitro. Am J Respir Crit Care Med 2000; 161: 595–600